News

Saab describes historical and ongoing unmet needs in Wilson disease, highlighting recent progress but also the need for a streamlined diagnosis.

This interview with Ian Myles, MD, MPH, highlights his team’s recent findings on identifying dermatitis related to topical steroid withdrawal (TSW) versus atopic dermatitis.

Patients with hereditary angioedema report greater rates of autoimmune diseases, allergies, and asthma than the general population, highlighting key comorbidities.

Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.

A new cross-sectional study found that the odds of having bronchodilator responsiveness declined by 8% per hour during the working day.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

A trio of nephrology experts discuss the significance of iptacopan’s FDA approval as the first treatment for C3G.

These data highlight differences and similarities among dermatologists globally in their decisions related to the treatment of mild-to-moderate atopic dermatitis.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key allergy updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.

Lammert discusses the shifting landscape of treatment response metrics and the latest advancements in second-line therapy for PBC.

Baricitinib treatment was safe among patients with alopecia areata over 48 weeks in a real-world treatment setting.

Martinez explains the pathophysiology and clinical presentation of pruritus in children with cholestatic liver disease as well as treatment options.

Examining recent developments in ASUC management, including predictive markers for colectomy, new treatment approaches, and ongoing challenges.

The approval expands the indication for vutrisiran, which becomes the first therapeutic approved by the FDA for the treatment of ATTR-CM.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode highlights 5 key dermatology updates from the 2025 American Academy of Dermatology Annual Meeting in Orlando.

A new systematic review finds IV iron effective for iron non-responders but calls for further studies on the causes of oral iron failure.

Climate change worsens allergies by lengthening pollen seasons, increasing air pollution, and driving new food allergies. Experts offer strategies for clinicians.

Schilsky provides an overview of Wilson disease and describes optimal management strategies, highlighting the importance of early detection and intervention.

Mitchell describes the “paradox” hepatologists face in the management of ALD and the importance of early intervention for improving outcomes.

Investigators highlight systemic treatments for psoriatic disease that maintain lower rates of serious infections among older adults suffering from psoriatic disease.

A study highlights how food allergies impact adults' mental health and social lives, revealing anxiety, isolation, and the need for better support systems.

In the final segment of this 6-part RX Review, experts discuss key concepts from the USMSTF guidance where evidence is limited.

In the fifth segment of this 6-part RX Review, experts discuss areas where more research is needed on bowel preparation for colonoscopy.

In the fourth segment of this 6-part RX Review, experts discuss potential barriers to implementation of the USMSTF guidance and compliance challenges.

In the third segment of this 6-part RX Review, experts discuss key updates from the previous 2014 iteration of the USMSTF guidance.

In the second segment of this 6-part RX Review, experts discuss benchmarks for assessing adequate bowel preparation and the need for standardized scoring.